Although data directly linking rheumatoid arthritis to prostate cancer risk remain limited, the persistent systemic elevations of TNF-α, IL-6, and IL-1β observed in active disease mirror the inflammatory signatures associated with high-grade and aggressive prostate cancer, providing a biologically plausible pathway through which systemic autoimmune inflammation could influence prostate carcinogenesis [30-32]. Here, IL1B is linked to prostate carcinoma.